| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-A2 Antigen | 19 | 2024 | 172 | 5.650 |
Why?
|
| Myeloblastin | 15 | 2018 | 65 | 3.340 |
Why?
|
| T-Lymphocytes, Cytotoxic | 27 | 2021 | 1020 | 2.780 |
Why?
|
| Antigens, Neoplasm | 18 | 2020 | 1580 | 2.630 |
Why?
|
| T-Lymphocytes | 33 | 2024 | 3949 | 2.370 |
Why?
|
| Leukocyte Elastase | 7 | 2017 | 71 | 2.050 |
Why?
|
| Cancer Vaccines | 12 | 2020 | 754 | 1.970 |
Why?
|
| Leukemia, Myeloid, Acute | 23 | 2024 | 7265 | 1.740 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 20 | 2018 | 2635 | 1.440 |
Why?
|
| Leukemia | 9 | 2024 | 1719 | 1.430 |
Why?
|
| Graft vs Host Disease | 30 | 2024 | 2810 | 1.430 |
Why?
|
| Fetal Blood | 7 | 2016 | 501 | 1.260 |
Why?
|
| Cross-Priming | 4 | 2018 | 40 | 1.240 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2024 | 1840 | 1.240 |
Why?
|
| Peptides | 13 | 2021 | 1504 | 1.160 |
Why?
|
| Peptide Fragments | 9 | 2018 | 1309 | 1.150 |
Why?
|
| Myelodysplastic Syndromes | 16 | 2024 | 3156 | 1.150 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2024 | 1137 | 1.110 |
Why?
|
| Leukemia, Myeloid | 7 | 2016 | 993 | 1.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 31 | 2024 | 7044 | 1.090 |
Why?
|
| Cytotoxicity, Immunologic | 14 | 2019 | 683 | 1.050 |
Why?
|
| Epitopes, T-Lymphocyte | 7 | 2020 | 228 | 1.000 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2019 | 1655 | 1.000 |
Why?
|
| Leukocytes, Mononuclear | 6 | 2021 | 714 | 0.850 |
Why?
|
| Transplantation, Homologous | 30 | 2023 | 3046 | 0.820 |
Why?
|
| Antigen Presentation | 4 | 2018 | 286 | 0.810 |
Why?
|
| CD4-Positive T-Lymphocytes | 14 | 2018 | 1051 | 0.810 |
Why?
|
| Graft vs Leukemia Effect | 7 | 2018 | 107 | 0.780 |
Why?
|
| Epitopes | 7 | 2016 | 707 | 0.720 |
Why?
|
| Neoplasm Proteins | 7 | 2018 | 3345 | 0.720 |
Why?
|
| Antigen-Presenting Cells | 6 | 2024 | 286 | 0.720 |
Why?
|
| Lymphocyte Activation | 18 | 2019 | 1723 | 0.690 |
Why?
|
| Immunomodulation | 4 | 2018 | 255 | 0.680 |
Why?
|
| Immunotherapy | 12 | 2023 | 3557 | 0.680 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 282 | 0.650 |
Why?
|
| Minor Histocompatibility Antigens | 4 | 2018 | 115 | 0.650 |
Why?
|
| Cyclins | 1 | 2020 | 467 | 0.610 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 3035 | 0.600 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 367 | 0.600 |
Why?
|
| Cyclin E | 1 | 2020 | 283 | 0.590 |
Why?
|
| Absorption, Physiological | 1 | 2017 | 6 | 0.580 |
Why?
|
| Neutrophils | 4 | 2018 | 873 | 0.580 |
Why?
|
| Bone Marrow Transplantation | 17 | 2009 | 1757 | 0.580 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 40 | 0.570 |
Why?
|
| HLA Antigens | 6 | 2016 | 594 | 0.570 |
Why?
|
| Serine Proteases | 1 | 2017 | 19 | 0.570 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 88 | 0.550 |
Why?
|
| Serine Endopeptidases | 6 | 2003 | 275 | 0.540 |
Why?
|
| Hematologic Neoplasms | 14 | 2019 | 1956 | 0.540 |
Why?
|
| Antilymphocyte Serum | 5 | 2002 | 237 | 0.540 |
Why?
|
| Humans | 140 | 2024 | 270740 | 0.530 |
Why?
|
| Immunity, Cellular | 8 | 2019 | 440 | 0.520 |
Why?
|
| Complement System Proteins | 2 | 2019 | 135 | 0.510 |
Why?
|
| Animals | 39 | 2024 | 61956 | 0.450 |
Why?
|
| Caspase 9 | 1 | 2014 | 187 | 0.440 |
Why?
|
| Lymphocyte Transfusion | 6 | 2010 | 174 | 0.440 |
Why?
|
| Mice | 31 | 2024 | 35600 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 878 | 0.430 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2017 | 593 | 0.430 |
Why?
|
| Bone Marrow | 7 | 2024 | 2441 | 0.430 |
Why?
|
| Cell Line, Tumor | 18 | 2024 | 14849 | 0.420 |
Why?
|
| Transgenes | 1 | 2014 | 576 | 0.400 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1335 | 0.400 |
Why?
|
| WT1 Proteins | 1 | 2012 | 107 | 0.390 |
Why?
|
| Mice, Inbred NOD | 3 | 2024 | 896 | 0.390 |
Why?
|
| Immunophenotyping | 9 | 2019 | 1726 | 0.380 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 401 | 0.360 |
Why?
|
| Stem Cell Transplantation | 4 | 2019 | 1418 | 0.360 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2016 | 372 | 0.360 |
Why?
|
| Pancytopenia | 4 | 2004 | 119 | 0.350 |
Why?
|
| Vaccination | 4 | 2016 | 1166 | 0.340 |
Why?
|
| Cell Proliferation | 9 | 2018 | 7238 | 0.340 |
Why?
|
| Granulocytes | 1 | 2010 | 244 | 0.340 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2017 | 247 | 0.340 |
Why?
|
| Vaccines, Subunit | 3 | 2017 | 128 | 0.340 |
Why?
|
| Mice, SCID | 4 | 2021 | 1826 | 0.340 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 4 | 2010 | 73 | 0.340 |
Why?
|
| T-Cell Antigen Receptor Specificity | 3 | 2016 | 92 | 0.330 |
Why?
|
| Interferon-alpha | 3 | 2010 | 959 | 0.330 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 2328 | 0.330 |
Why?
|
| Research Support as Topic | 1 | 2010 | 120 | 0.330 |
Why?
|
| Graft vs Tumor Effect | 8 | 2010 | 143 | 0.320 |
Why?
|
| Immunosuppressive Agents | 9 | 2006 | 1432 | 0.320 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 262 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2018 | 593 | 0.310 |
Why?
|
| Mice, Inbred BALB C | 9 | 2024 | 2454 | 0.310 |
Why?
|
| Cell Line | 7 | 2024 | 5338 | 0.310 |
Why?
|
| Adult | 46 | 2024 | 82040 | 0.310 |
Why?
|
| Immunologic Memory | 6 | 2016 | 380 | 0.300 |
Why?
|
| Dendritic Cells | 7 | 2019 | 1110 | 0.300 |
Why?
|
| Cytokines | 7 | 2024 | 2825 | 0.290 |
Why?
|
| Bacteroides | 2 | 2024 | 54 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 3917 | 0.280 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 16215 | 0.280 |
Why?
|
| Flow Cytometry | 14 | 2012 | 3045 | 0.270 |
Why?
|
| Colon, Sigmoid | 1 | 2006 | 42 | 0.270 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 425 | 0.270 |
Why?
|
| Amino Acid Sequence | 6 | 2017 | 4567 | 0.260 |
Why?
|
| Immunological Synapses | 2 | 2024 | 31 | 0.260 |
Why?
|
| Autoantibodies | 2 | 2019 | 602 | 0.260 |
Why?
|
| Female | 52 | 2024 | 148940 | 0.260 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 1129 | 0.260 |
Why?
|
| Neutropenia | 3 | 2022 | 1006 | 0.250 |
Why?
|
| Cathepsin G | 2 | 2016 | 22 | 0.240 |
Why?
|
| Male | 46 | 2024 | 128315 | 0.240 |
Why?
|
| Hookworm Infections | 1 | 2006 | 124 | 0.240 |
Why?
|
| Cells, Cultured | 10 | 2018 | 5694 | 0.240 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 980 | 0.240 |
Why?
|
| Unrelated Donors | 3 | 2018 | 321 | 0.230 |
Why?
|
| Single-Chain Antibodies | 1 | 2024 | 61 | 0.230 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 183 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2015 | 1367 | 0.230 |
Why?
|
| Lymphocyte Count | 6 | 2016 | 485 | 0.220 |
Why?
|
| Melanoma | 5 | 2013 | 5595 | 0.220 |
Why?
|
| Cell Culture Techniques | 4 | 2018 | 575 | 0.220 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2003 | 56 | 0.220 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2023 | 40 | 0.210 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1424 | 0.210 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 2351 | 0.210 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 441 | 0.210 |
Why?
|
| Leukemia, Lymphoid | 1 | 2003 | 289 | 0.210 |
Why?
|
| Anemia, Aplastic | 3 | 2002 | 232 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2024 | 282 | 0.210 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2013 | 1032 | 0.200 |
Why?
|
| Transplantation Conditioning | 11 | 2019 | 2374 | 0.200 |
Why?
|
| Immunization | 1 | 2004 | 399 | 0.200 |
Why?
|
| Middle Aged | 39 | 2024 | 90352 | 0.200 |
Why?
|
| Antibody Formation | 2 | 2019 | 386 | 0.200 |
Why?
|
| Herpesvirus 4, Human | 5 | 2010 | 961 | 0.200 |
Why?
|
| Immunity | 1 | 2004 | 354 | 0.200 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 247 | 0.200 |
Why?
|
| Skin Neoplasms | 3 | 2013 | 4895 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| U937 Cells | 3 | 2016 | 178 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 12033 | 0.180 |
Why?
|
| Peroxidase | 1 | 2021 | 133 | 0.180 |
Why?
|
| Hematopoiesis | 4 | 2007 | 602 | 0.180 |
Why?
|
| Immune System | 3 | 2009 | 275 | 0.180 |
Why?
|
| K562 Cells | 3 | 2016 | 344 | 0.180 |
Why?
|
| Antibody Specificity | 2 | 2019 | 336 | 0.180 |
Why?
|
| Lovastatin | 2 | 2010 | 56 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 109 | 0.170 |
Why?
|
| Killer Cells, Natural | 5 | 2010 | 965 | 0.170 |
Why?
|
| Aged | 26 | 2021 | 73333 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 5759 | 0.170 |
Why?
|
| Methotrexate | 1 | 2023 | 1025 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 7381 | 0.170 |
Why?
|
| Antibodies | 2 | 2012 | 809 | 0.160 |
Why?
|
| Antibodies, Blocking | 2 | 2017 | 95 | 0.160 |
Why?
|
| Graft vs Host Reaction | 5 | 1998 | 62 | 0.160 |
Why?
|
| Cricetulus | 1 | 2019 | 214 | 0.160 |
Why?
|
| Models, Immunological | 1 | 2018 | 79 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 513 | 0.160 |
Why?
|
| Amino Acid Motifs | 2 | 2017 | 399 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2007 | 185 | 0.160 |
Why?
|
| CHO Cells | 1 | 2019 | 320 | 0.160 |
Why?
|
| Models, Genetic | 2 | 2013 | 1163 | 0.160 |
Why?
|
| Stem Cells | 3 | 2011 | 1216 | 0.150 |
Why?
|
| Leukemia, T-Cell | 3 | 2003 | 90 | 0.150 |
Why?
|
| Complement Activation | 1 | 2018 | 93 | 0.150 |
Why?
|
| Myeloablative Agonists | 2 | 2019 | 388 | 0.150 |
Why?
|
| Biomarkers | 4 | 2019 | 5051 | 0.150 |
Why?
|
| Mutation | 2 | 2024 | 15912 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 5002 | 0.140 |
Why?
|
| Lymphocytes | 4 | 2011 | 1275 | 0.140 |
Why?
|
| Bortezomib | 1 | 2019 | 549 | 0.140 |
Why?
|
| Solubility | 1 | 2017 | 247 | 0.140 |
Why?
|
| Ligands | 2 | 2017 | 1012 | 0.140 |
Why?
|
| Natural Killer T-Cells | 1 | 2018 | 121 | 0.140 |
Why?
|
| Vaccines, DNA | 2 | 2011 | 111 | 0.140 |
Why?
|
| Biological Transport | 1 | 2018 | 626 | 0.140 |
Why?
|
| Protein Binding | 4 | 2019 | 3485 | 0.140 |
Why?
|
| Cytomegalovirus | 4 | 2010 | 496 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 929 | 0.140 |
Why?
|
| Genotype | 3 | 2016 | 4252 | 0.130 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 52 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2010 | 5438 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 4 | 2016 | 4481 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2010 | 3844 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 64 | 0.130 |
Why?
|
| Exosomes | 1 | 2019 | 255 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 271 | 0.130 |
Why?
|
| Cell Separation | 3 | 2012 | 609 | 0.130 |
Why?
|
| Disease Progression | 2 | 2024 | 6867 | 0.130 |
Why?
|
| Remission Induction | 3 | 2010 | 3656 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 16689 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 3028 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 3 | 2010 | 1456 | 0.130 |
Why?
|
| Kinetics | 2 | 2017 | 2220 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2018 | 1570 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 968 | 0.120 |
Why?
|
| Allografts | 4 | 2019 | 686 | 0.120 |
Why?
|
| Antigens, CD34 | 4 | 2012 | 640 | 0.120 |
Why?
|
| Melphalan | 4 | 2019 | 879 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2014 | 103 | 0.120 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2014 | 23 | 0.120 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 1125 | 0.120 |
Why?
|
| Trastuzumab | 1 | 2017 | 743 | 0.120 |
Why?
|
| Graft Survival | 3 | 2016 | 1083 | 0.120 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 51 | 0.120 |
Why?
|
| Genetic Therapy | 2 | 2016 | 1716 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2017 | 669 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 672 | 0.110 |
Why?
|
| CD13 Antigens | 1 | 2013 | 43 | 0.110 |
Why?
|
| Young Adult | 7 | 2021 | 22251 | 0.110 |
Why?
|
| Myeloid Cells | 2 | 2013 | 273 | 0.110 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 362 | 0.110 |
Why?
|
| Rituximab | 1 | 2019 | 1594 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 714 | 0.110 |
Why?
|
| Genome, Human | 2 | 2012 | 1888 | 0.110 |
Why?
|
| Transplantation, Heterologous | 2 | 2018 | 1054 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2013 | 105 | 0.110 |
Why?
|
| Blood Platelets | 2 | 2015 | 677 | 0.110 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 219 | 0.110 |
Why?
|
| Protein Transport | 2 | 2012 | 737 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 359 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 227 | 0.110 |
Why?
|
| Gene Frequency | 3 | 2012 | 1246 | 0.110 |
Why?
|
| Neoplasms | 6 | 2022 | 15927 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2016 | 9292 | 0.110 |
Why?
|
| RNA Interference | 1 | 2017 | 1388 | 0.100 |
Why?
|
| Bone Marrow Diseases | 2 | 2004 | 186 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2013 | 76 | 0.100 |
Why?
|
| Mucus | 2 | 2022 | 109 | 0.100 |
Why?
|
| Azacitidine | 1 | 2019 | 1218 | 0.100 |
Why?
|
| CD40 Antigens | 1 | 2012 | 106 | 0.100 |
Why?
|
| Complement C3 | 1 | 2012 | 80 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 4644 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 1739 | 0.100 |
Why?
|
| Lymphocyte Depletion | 3 | 2004 | 316 | 0.100 |
Why?
|
| Vidarabine | 3 | 2019 | 1384 | 0.100 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2011 | 35 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 6685 | 0.100 |
Why?
|
| fas Receptor | 2 | 2011 | 197 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 140 | 0.100 |
Why?
|
| Genomic Imprinting | 1 | 2012 | 199 | 0.100 |
Why?
|
| Mucins | 2 | 2022 | 289 | 0.090 |
Why?
|
| Mice, Transgenic | 6 | 2018 | 4223 | 0.090 |
Why?
|
| Tissue Donors | 3 | 2011 | 821 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2011 | 104 | 0.090 |
Why?
|
| Base Sequence | 4 | 2012 | 5437 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 205 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2012 | 259 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 7100 | 0.090 |
Why?
|
| Survival Rate | 8 | 2019 | 12541 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2012 | 163 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 1642 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2011 | 232 | 0.090 |
Why?
|
| Receptors, IgG | 1 | 2011 | 116 | 0.090 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 1089 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 4130 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2016 | 33737 | 0.090 |
Why?
|
| Cytogenetic Analysis | 2 | 2010 | 574 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 1067 | 0.090 |
Why?
|
| Virus Activation | 3 | 2019 | 237 | 0.090 |
Why?
|
| Cell Differentiation | 5 | 2014 | 4116 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 345 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 784 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2019 | 9470 | 0.090 |
Why?
|
| Financing, Organized | 1 | 2010 | 21 | 0.090 |
Why?
|
| Budgets | 1 | 2010 | 24 | 0.090 |
Why?
|
| Blood Cell Count | 3 | 2012 | 233 | 0.090 |
Why?
|
| Receptors, CCR5 | 1 | 2009 | 55 | 0.090 |
Why?
|
| CD3 Complex | 3 | 2023 | 320 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 49 | 0.090 |
Why?
|
| Transplantation Immunology | 1 | 2009 | 107 | 0.090 |
Why?
|
| Metals | 1 | 2010 | 148 | 0.090 |
Why?
|
| DNA Primers | 1 | 2012 | 1496 | 0.080 |
Why?
|
| Lysosomes | 1 | 2012 | 345 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 2359 | 0.080 |
Why?
|
| Viral Matrix Proteins | 2 | 2010 | 181 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 3 | 2001 | 219 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2012 | 2486 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 1586 | 0.080 |
Why?
|
| Ubiquitination | 1 | 2012 | 579 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2010 | 1179 | 0.080 |
Why?
|
| Cell Adhesion | 4 | 2017 | 1028 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2010 | 96 | 0.080 |
Why?
|
| Aminoglycosides | 1 | 2010 | 233 | 0.080 |
Why?
|
| Disease-Free Survival | 8 | 2019 | 10265 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4048 | 0.080 |
Why?
|
| Computational Biology | 1 | 2015 | 1291 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 30998 | 0.080 |
Why?
|
| Leukocytes | 1 | 2011 | 421 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2014 | 6224 | 0.080 |
Why?
|
| Phenotype | 6 | 2013 | 6509 | 0.080 |
Why?
|
| Genes, Homeobox | 2 | 2014 | 142 | 0.080 |
Why?
|
| Premature Birth | 1 | 2013 | 408 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 274 | 0.080 |
Why?
|
| Antigens, CD | 3 | 2016 | 1418 | 0.080 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2008 | 34 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 3597 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 295 | 0.070 |
Why?
|
| Clone Cells | 3 | 2007 | 591 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2016 | 2375 | 0.070 |
Why?
|
| Cell Movement | 2 | 2017 | 2472 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 1828 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2651 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 2573 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2011 | 847 | 0.070 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 220 | 0.070 |
Why?
|
| Data Display | 1 | 2006 | 49 | 0.070 |
Why?
|
| Apoptosis | 3 | 2017 | 7757 | 0.070 |
Why?
|
| Bronchi | 1 | 2008 | 325 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2003 | 195 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2009 | 1497 | 0.070 |
Why?
|
| HLA-DR Antigens | 3 | 2002 | 184 | 0.070 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 584 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 1710 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 65 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2000 | 770 | 0.070 |
Why?
|
| Ancylostomatoidea | 1 | 2006 | 60 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 797 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2399 | 0.060 |
Why?
|
| Software | 1 | 2013 | 1355 | 0.060 |
Why?
|
| Cyclosporine | 2 | 2003 | 292 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2018 | 2353 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 9042 | 0.060 |
Why?
|
| Anemia, Refractory | 2 | 2002 | 40 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7655 | 0.060 |
Why?
|
| Transplantation Chimera | 3 | 2012 | 174 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5149 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 4795 | 0.060 |
Why?
|
| Genes, ras | 1 | 2008 | 679 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 17 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 2 | 2007 | 495 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 885 | 0.060 |
Why?
|
| Regeneration | 1 | 2007 | 284 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 315 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6256 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2010 | 2033 | 0.060 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 64 | 0.060 |
Why?
|
| Heterografts | 2 | 2017 | 738 | 0.060 |
Why?
|
| Drug Design | 1 | 2006 | 372 | 0.060 |
Why?
|
| HLA-DR4 Antigen | 1 | 2003 | 9 | 0.060 |
Why?
|
| Lymphoma | 3 | 2007 | 1519 | 0.060 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 96 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 4831 | 0.060 |
Why?
|
| Exanthema | 1 | 2006 | 212 | 0.060 |
Why?
|
| Transcriptome | 1 | 2012 | 1963 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2014 | 30 | 0.060 |
Why?
|
| Adolescent | 11 | 2021 | 32767 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2021 | 13414 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2018 | 383 | 0.050 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1386 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2024 | 152 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2003 | 36 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2014 | 149 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 2 | 2002 | 206 | 0.050 |
Why?
|
| HLA-DR2 Antigen | 1 | 2002 | 11 | 0.050 |
Why?
|
| Xylose | 1 | 2022 | 18 | 0.050 |
Why?
|
| Gene Library | 1 | 2024 | 353 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2018 | 170 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 73 | 0.050 |
Why?
|
| CD4 Antigens | 3 | 2010 | 170 | 0.050 |
Why?
|
| HL-60 Cells | 2 | 2014 | 318 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2023 | 179 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 9039 | 0.050 |
Why?
|
| Podophyllotoxin | 2 | 2019 | 66 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 255 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2002 | 44 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 661 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 63 | 0.050 |
Why?
|
| Carmustine | 2 | 2019 | 225 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 105 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 3640 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 848 | 0.050 |
Why?
|
| Histocompatibility Testing | 4 | 2007 | 487 | 0.050 |
Why?
|
| Xenopus Proteins | 1 | 2002 | 193 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 195 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 5776 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5257 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2005 | 699 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2006 | 1712 | 0.050 |
Why?
|
| Cryoglobulinemia | 1 | 2000 | 21 | 0.050 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 2001 | 88 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2000 | 31 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2024 | 611 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2016 | 427 | 0.050 |
Why?
|
| Feces | 1 | 2024 | 861 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2014 | 12103 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2002 | 520 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2019 | 2090 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 1094 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2009 | 1465 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 5866 | 0.040 |
Why?
|
| Cladribine | 1 | 2001 | 253 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 1101 | 0.040 |
Why?
|
| MART-1 Antigen | 2 | 2010 | 113 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 1996 | 71 | 0.040 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 16 | 0.040 |
Why?
|
| Cyclopentanes | 2 | 1996 | 42 | 0.040 |
Why?
|
| CD28 Antigens | 2 | 2013 | 202 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 1571 | 0.040 |
Why?
|
| Peptide Library | 2 | 2011 | 148 | 0.040 |
Why?
|
| Interleukin-2 | 3 | 2009 | 889 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 271 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1996 | 189 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 160 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 230 | 0.040 |
Why?
|
| CD57 Antigens | 2 | 2012 | 22 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 175 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 1 | 1998 | 253 | 0.040 |
Why?
|
| Platelet Transfusion | 2 | 2015 | 166 | 0.040 |
Why?
|
| Retroviridae | 1 | 2019 | 373 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 178 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5574 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3409 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 2166 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 707 | 0.040 |
Why?
|
| CD8 Antigens | 2 | 2010 | 174 | 0.040 |
Why?
|
| Biological Assay | 1 | 1999 | 178 | 0.040 |
Why?
|
| Jurkat Cells | 2 | 2010 | 319 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2000 | 366 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1997 | 230 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1485 | 0.040 |
Why?
|
| Exons | 2 | 1999 | 1383 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 870 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 1998 | 255 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 3339 | 0.030 |
Why?
|
| Platelet Count | 1 | 1997 | 492 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 1999 | 1557 | 0.030 |
Why?
|
| Lymphopenia | 1 | 1998 | 211 | 0.030 |
Why?
|
| Cytarabine | 2 | 2019 | 2014 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 164 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1553 | 0.030 |
Why?
|
| Cell Count | 1 | 1996 | 512 | 0.030 |
Why?
|
| Genes, rel | 1 | 2014 | 8 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 676 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 106 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2014 | 71 | 0.030 |
Why?
|
| Hemorrhage | 1 | 1999 | 727 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 398 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Busulfan | 1 | 2019 | 794 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1477 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2014 | 53 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 88 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 151 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2014 | 84 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 1437 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1999 | 755 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2014 | 1824 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2013 | 64 | 0.030 |
Why?
|
| Secondary Prevention | 2 | 2010 | 311 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 5457 | 0.030 |
Why?
|
| Recurrence | 4 | 2007 | 4878 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 22505 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 419 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 657 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2012 | 41 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2012 | 2422 | 0.030 |
Why?
|
| Isoantigens | 1 | 2012 | 66 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 202 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 544 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1097 | 0.030 |
Why?
|
| Blood Component Removal | 2 | 2004 | 119 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 14 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cathepsin B | 1 | 2011 | 35 | 0.020 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 35 | 0.020 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2011 | 53 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2014 | 483 | 0.020 |
Why?
|
| Cell Communication | 1 | 2014 | 512 | 0.020 |
Why?
|
| Models, Biological | 2 | 2011 | 3194 | 0.020 |
Why?
|
| Proteomics | 1 | 2019 | 1427 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2011 | 85 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2011 | 63 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2005 | 172 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2011 | 87 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Alleles | 2 | 2012 | 2600 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1997 | 3530 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 2010 | 28 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1461 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 118 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2010 | 98 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 294 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2014 | 757 | 0.020 |
Why?
|
| Disulfides | 1 | 2010 | 111 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 1002 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2009 | 97 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2009 | 48 | 0.020 |
Why?
|
| Lip | 1 | 2009 | 35 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 260 | 0.020 |
Why?
|
| Peyer's Patches | 1 | 2009 | 31 | 0.020 |
Why?
|
| Whole-Body Irradiation | 2 | 2003 | 323 | 0.020 |
Why?
|
| Langerhans Cells | 1 | 2009 | 53 | 0.020 |
Why?
|
| Microtubule-Organizing Center | 1 | 2009 | 9 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 3187 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7914 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Cause of Death | 1 | 2012 | 789 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2010 | 278 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1136 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2009 | 61 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1563 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 336 | 0.020 |
Why?
|
| Carcinoma | 1 | 2000 | 2610 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2019 | 2765 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1012 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 1099 | 0.020 |
Why?
|
| Gonanes | 1 | 2008 | 50 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2250 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 1060 | 0.020 |
Why?
|
| Child | 5 | 2011 | 30559 | 0.020 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 14617 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 1472 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3063 | 0.020 |
Why?
|
| Mitosis | 1 | 2009 | 681 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 639 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1542 | 0.020 |
Why?
|
| Brefeldin A | 2 | 1996 | 22 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2069 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2007 | 311 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1525 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 416 | 0.020 |
Why?
|
| Pre-B Cell Receptors | 1 | 2005 | 5 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2010 | 1138 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2000 | 2067 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2005 | 70 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2010 | 1038 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2665 | 0.010 |
Why?
|
| Skin | 1 | 2009 | 1271 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1584 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15218 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 10708 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5728 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 3484 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2005 | 174 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 788 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2006 | 909 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5315 | 0.010 |
Why?
|
| HLA-DR Serological Subtypes | 1 | 2002 | 5 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 296 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2003 | 120 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 904 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2010 | 801 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6390 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 1441 | 0.010 |
Why?
|
| Xenopus | 1 | 2002 | 237 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 2001 | 70 | 0.010 |
Why?
|
| Fibrinogens, Abnormal | 1 | 2000 | 6 | 0.010 |
Why?
|
| Cryoglobulins | 1 | 2000 | 11 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 67 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2002 | 498 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 354 | 0.010 |
Why?
|
| Megakaryocytes | 1 | 2001 | 129 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 938 | 0.010 |
Why?
|
| Mesna | 1 | 2000 | 67 | 0.010 |
Why?
|
| Anemia, Sideroblastic | 1 | 2001 | 57 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 194 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 1430 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4328 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 8130 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8699 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2000 | 358 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 1144 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 605 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2904 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 595 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 192 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 436 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 13006 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 1063 | 0.010 |
Why?
|
| Adenosine | 1 | 2001 | 294 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2009 | 3077 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1999 | 105 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 822 | 0.010 |
Why?
|
| Risk Factors | 2 | 2007 | 17888 | 0.010 |
Why?
|
| Etoposide | 1 | 2000 | 907 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 5162 | 0.010 |
Why?
|
| Immunoassay | 1 | 1998 | 214 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1958 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 120 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 467 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1998 | 735 | 0.010 |
Why?
|
| Chloroquine | 1 | 1996 | 63 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 14012 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1996 | 55 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1996 | 85 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5408 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 427 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 2493 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 1697 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1996 | 581 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 4492 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 3245 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 17061 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 5824 | 0.000 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1998 | 2903 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2005 | 39890 | 0.000 |
Why?
|